shutterstock_1569359980_Sundry Photography
7 March 2023Big PharmaMuireann Bolger
Gilead defeats immunity bid in hepatitis C patent case
The University of Minnesota had raised three key issue on appeal | Sovereign immunity was at the heart of the years-long dispute.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
10 January 2023 Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.
Big Pharma
18 October 2022 Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.
Editor's picks
Editor's picks
Americas
10 January 2023 Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.
Big Pharma
18 October 2022 Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.
Americas
10 January 2023 Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.
Big Pharma
18 October 2022 Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.